Sugi Predict

Sugi Predict / Compounds / SCHEMBL1978043

SCHEMBL1978043

SCHEMBL1978043

CCC(C)CCCN1CCCC1=O

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ PIK3CD O00329 1/20 0.51
▸ ADRA1B P35368 4/20 0.43
▸ KMT2A Q03164 2/20 0.43
▸ MEN1 O00255 1/20 0.43
▸ PKM P14618 1/20 0.43
▸ LMNA P02545 2/20 0.41
▸ CA12 O43570 1/20 0.41
▸ CA1 P00915 1/20 0.41
▸ CA2 P00918 1/20 0.41
▸ CA3 P07451 1/20 0.41
▸ CA4 P22748 1/20 0.41
▸ CA6 P23280 1/20 0.41
▸ CA5A P35218 1/20 0.41
▸ CA7 P43166 1/20 0.41
▸ CA9 Q16790 1/20 0.41
▸ CA13 Q8N1Q1 1/20 0.41
▸ CA14 Q9ULX7 1/20 0.41
▸ CA5B Q9Y2D0 1/20 0.41
▸ RAB9A P51151 3/20 0.41
▸ MALT1 Q9UDY8 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21207378 0.90 PIK3CD (0.55) PIK3CDADRA1BKMT2AMEN1PKM
SCHEMBL5499961 0.89 PIK3CD (0.50) PIK3CDADRA1BKMT2AMEN1PKM
SCHEMBL7005443 0.87 PIK3CD (0.61) PIK3CDADRA1BKMT2AMEN1PKM
SCHEMBL5501695 0.86 PIK3CD (0.47) PIK3CDADRA1BKMT2AMEN1PKM
SCHEMBL5914541 0.85 PIK3CD (0.49) PIK3CDADRA1BKMT2AMEN1PKM
SCHEMBL104477 0.84 PIK3CD (0.61) PIK3CDADRA1BKMT2AMEN1PKM
SCHEMBL4336427 0.84 PIK3CD (0.49) PIK3CDADRA1BKMT2AMEN1PKM
SCHEMBL4329356 0.83 PIK3CD (0.47) PIK3CDADRA1BKMT2AMEN1PKM
SCHEMBL1980364 0.83 PIK3CD (0.47) PIK3CDADRA1BKMT2AMEN1PKM
SCHEMBL9018951 0.82 PIK3CD (0.50) PIK3CDADRA1BKMT2AMEN1PKM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4626972-A1 CONJUGATES OF POLYSACCHARIDES AND HYDROPHOBIC COMPOUNDS AS EMULSION STABILIZERS BASF SE (DE) 2025-10-08 — — EP disclosed
WO-2024115355-A1 CONJUGATES OF POLYSACCHARIDES AND HYDROPHOBIC COMPOUNDS AS EMULSION STABILIZERS BASF SE (DE) 2024-06-06 — — WO disclosed
US-9551721-B2 Identification of small molecules recognized by antibodies in subjects with neurodegenerative diseases THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) 2017-01-24 — — US disclosed
US-9545104-B2 Liquid suspension concentrate formulations containing saflufenacil and glyphosate BASF SE (DE) 2017-01-17 — — US disclosed
EP-2855546-A1 CONTACT LENSES COMPRISING WATER SOLUBLE N-(2 HYDROXYALKYL) (METH)ACRYLAMIDE POLYMERS OR COPOLYMERS Johnson & Johnson Vision Care Inc. (US) 2015-04-08 — — EP disclosed
US-8703650-B2 Liquid suspension concentrate formulations containing saflufenacil BASF SE (DE) 2014-04-22 — — US disclosed
WO-2013177513-A1 CONTACT LENSES COMPRISING WATER SOLUBLE N-(2 HYDROXYALKYL) (METH)ACRYLAMIDE POLYMERS OR COPOLYMERS JOHNSON & JOHNSON VISION CARE, INC. (US) 2013-11-28 — — WO disclosed
US-20120302444-A1 LIQUID SUSPENSION CONCENTRATE FORMULATIONS CONTAINING SAFLUFENACIL BASF SE (DE) 2012-11-29 — — US disclosed
EP-2509422-A1 LIQUID SUSPENSION CONCENTRATE FORMULATIONS CONTAINING SAFLUFENACIL AND GLYPHOSATE BASF SE (DE) 2012-10-17 — — EP disclosed
US-20120231954-A1 LIQUID SUSPENSION CONCENTRATE FORMULATIONS CONTAINING SAFLUFENACIL AND GLYPHOSATE BASF SE (DE) 2012-09-13 — — US disclosed
CN-102651971-A Liquid suspension concentrate formulations containing saflufenacil and glyphosate BASF SE 2012-08-29 — — CN disclosed
WO-2011070054-A1 LIQUID SUSPENSION CONCENTRATE FORMULATIONS CONTAINING SAFLUFENACIL AND GLYPHOSATE BASF SE (DE) 2011-06-16 — — WO disclosed
WO-2011070051-A2 LIQUID SUSPENSION CONCENTRATE FORMULATIONS CONTAINING SAFLUFENACIL BASF SE (DE) 2011-06-16 — — WO disclosed
EP-1809344-A2 BIOMEDICAL DEVICES CONTAINING AMPHIPHILIC BLOCK COPOLYMERS Johnson and Johnson Vision Care, Inc. (US) 2007-07-25 — — EP disclosed
EP-1751247-A2 1,1,1,2,2,4,5,5,5-NONAFLUORO-4-(TRIFLUOROMETHYL)-3-PENTANONE COMPOSITIONS COMPRISING A HYDROFLUOROCARBON AND USES THEREOF E.I.Du pont de nemours and company (US) 2007-02-14 — — EP disclosed
EP-1751246-A2 1,1,1,2,2,4,5,5,5-NONAFLUORO-4-(TRIFLUOROMETHYL)-3-PENTANONE REFRIGERANT COMPOSITIONS COMPRISING A HYDROCARBON AND USES THEREOF E.I.Du pont de nemours and company (US) 2007-02-14 — — EP disclosed
WO-2006039467-A2 BIOMEDICAL DEVICES CONTAINING AMPHIPHILIC BLOCK COPOLYMERS JOHNSON & JOHNSON VISION CARE, INC. (US) 2006-04-13 — — WO disclosed
WO-2005119143-A2 1,1,1,2,2,4,5,5,5-NONAFLUORO-4-(TRIFLUOROMETHYL)-3-PENTANONE COMPOSITIONS COMPRISING A HYDROFLUOROCARBON AND USES THEREOF E.I. DUPONT DE NEMOURS AND COMPANY (US) 2005-12-15 — — WO disclosed
WO-2005119144-A2 1,1,1,2,2,4,5,5,5-NONAFLUORO-4-(TRIFLUOROMETHYL)-3-PENTANONE REFRIGERANT COMPOSITIONS COMPRISING A HYDROCARBON AND USES THEREOF E.I. DUPONT DE NEMOURS AND COMPANY (US) 2005-12-15 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120302444-A1 LIQUID SUSPENSION CONCENTRATE FORMULATIONS CONTAINING SAFLUFENACIL SCD5, FFAR3, FFAR2 PIK3CD 3316/4885ADRA1B 2502/4885KMT2A 305/4885
US-20120231954-A1 LIQUID SUSPENSION CONCENTRATE FORMULATIONS CONTAINING SAFLUFENACIL AND GLYPHOSATE PFAS, SLC6A5, AGXT PIK3CD 1639/4885ADRA1B 3456/4885KMT2A 726/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.